ACADIA PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $3.42B
- P/E (TTM)
- 9.0
- Dividend yield
- –
About Acadia Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Acadia Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies for neurological and rare diseases. The company operates two main commercial franchises focused on addressing underserved medical conditions. Its primary commercial products include Nuplazid, a treatment for hallucinations and delusions linked to Parkinson’s disease psychosis, and Daybue, approved for the treatment of Rett syndrome. Acadia distributes its pharmaceutical products through a specialized network of third-party specialty pharmacies and distributors to reach patients, healthcare providers, and caregivers.
The company maintains its global headquarters in San Diego, California. Beyond this main site, Acadia conducts substantial business operations in Princeton, New Jersey, and maintains European regional headquarters in Zug, Switzerland. The organization provides its commercial therapies across North America and pursues drug development initiatives intended for underserved patient communities worldwide.
Summary of the business section of Acadia Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ACADIA PHARMACEUTICALS INC
- Founded
- 1993
- Headquarters
- San Diego, CA
- Address
- 12830 El Camino Real, Suite 400 92130
- Phone
- (858) 558-2871
- Website
- www.acadia-pharm.com
- Employees
- 798, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, California
Stock & identifiers
- Ticker
- ACAD
- Exchange
- Nasdaq
- Shares outstanding
- 172M, Jul 28, 2026
- Public float
- $2.30B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1070494
- CUSIP
- 004225108
- ISIN
- US0042251084
- LEI
- 529900O3044NO0PEA039
- EIN
- 06-1376651
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Adams Catherine Owen | Chief Executive Officer, Director | 14,803 |
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | 82,120 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | 19,044 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | 13,088 |
| Jennifer J. Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | 11,280 |
| Thomas Garner | EVP, Chief Commercial Officer | – |
| Brendan Teehan | EVP, COO, HEAD OF COMMERCIAL | 62,105 |
| Bros. Advisors (GP) LLC Baker | Director | 3,761,611 |
| Brothers Life Sciences LP Baker | Director | 39,487,463 |
| Felix Baker | Director | 38,587,857 |
| 667, L.P. | Director | 39,132,562 |
| Bros. Advisors Lp Baker | Director | 39,452,627 |
| Julian Baker | Director | 39,433,853 |
| Jonathan Poole | Director | 2,010 |
| James M. Daly | Director | 12,148 |
| Edmund Harrigan | Director | 43,148 |
| Laura Brege | Director | 23,202 |
| Elizabeth A. Garofalo | Director | 33,489 |
| Adora Ndu | Director | 32,908 |
| Daniel B. Soland | Director | 44,041 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Catherine Owen Adams | $8.26M | $16.41M | $2.45M | $50 | $120 |
| FY2025 Stephen RDavis | $0 | $0 | $2.45M | $50 | $120 |
| FY2024 Catherine Owen Adams | $7.59M | $8.78M | $3.43M | $34 | $91 |
| FY2024 Stephen RDavis | $12.21M | -$919.39K | $3.43M | $34 | $91 |
| FY2023 Catherine Owen Adams | $0 | $0 | $2.96M | $59 | $92 |
| FY2023 Stephen R. Davis | $7.59M | $20.95M | $2.96M | $59 | $92 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“At December 31, 2025, we had a total of 798 employees, 796 of whom were full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 11, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 30, 2015 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 25, 2015 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 9, 2010 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 5, 2010 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 28, 2009 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |